Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Sarilumab |
Trade Name | Kevzara |
Synonyms | REGN88|SAR153191 |
Drug Descriptions |
Kevzara (sarilumab) is a monoclonal antibody that targets interleukin-6 receptor (IL6R), resulting in decreased downstream signaling and potentially leading to inhibition of tumor growth (Cancer Res 2012;72(8 Suppl):Abstract nr 2723). Kevzara (sarilumab) is FDA approved for use in patients with active rheumatoid arthritis (FDA.gov). |
DrugClasses | |
CAS Registry Number | 1189541-98-7 |
NCIT ID | C152302 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Capecitabine + Sarilumab | Capecitabine Sarilumab | 0 | 1 |
Cemiplimab + Sarilumab | Cemiplimab Sarilumab | 0 | 1 |
Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab | Ipilimumab Nivolumab and relatlimab-rmbw Sarilumab | 0 | 1 |
Sarilumab | Sarilumab | 0 | 0 |